Biodelivery Sciences
Biodelivery Sciences
WKN: 766464 / Symbol: BDSI / Name: Biodelivery Sci / Aktie / Pharmazeutika / Small Cap /
Stier
voraussichtlich
BDSI quite attractive at current levels
The overall risk/reward profile of this stock quite attractive at current levels.
Roth Capital reiterated its Buy rating and $4.50 a share price target on BDSI.
Roth's analyst notes,
"We
recently met with the management of BioDelivery Sciences. Our key
takeaway is that the share price driver over the coming six months is
likely to be prescription data for the pain drug Belbuca. Management
remains optimistic and the cash runway has recently been strengthened.
Maintain Buy rating. Key takeaways from our meetings with BDSI
management include: Business plan update. It appears that the sales
operation is already cash flow breakeven."
BDSI has secured two new U.S. patents covering all three of its FDA-approved products: BELBUCA (buprenorphine) buccal film, BUNAVAIL (buprenorphine and naloxone) buccal film and ONSOLIS (fentanyl buccal soluble film). One patent (U.S. Patent Application 15/212912) covers the composition of
the BioErodible MucoAdhesive drug delivery technology for BELBUCA and BUNAVAIL and the other ('288 patent) extends protection on ONSOLIS until July 2027.
Gesundheit | Biotechnologie | Vereinigte Staaten
$
BDSI quite attractive at current levels
The overall risk/reward profile of this stock quite attractive at current levels.
Roth Capital reiterated its Buy rating and $4.50 a share price target on BDSI.
Roth's analyst notes,
"We recently met with the management of BioDelivery Sciences. Our key takeaway is that the share price driver over the coming six months is likely to be prescription data for the pain drug Belbuca. Management remains optimistic and the cash runway has recently been strengthened. Maintain Buy rating. Key takeaways from our meetings with BDSI
management include: Business plan update. It appears that the sales operation is already cash flow breakeven."
BDSI has secured two new U.S. patents covering all three of its FDA-approved products: BELBUCA (buprenorphine) buccal film, BUNAVAIL (buprenorphine and naloxone) buccal film and ONSOLIS (fentanyl buccal soluble film). One patent (U.S. Patent Application 15/212912) covers the composition of
the BioErodible MucoAdhesive drug delivery technology for BELBUCA and BUNAVAIL and the other ('288 patent) extends protection on ONSOLIS until July 2027.
tamam stimmt der Buy-Einschätzung von klostergang zu
tamam stimmt am 22.05.2018 der Buy-Einschätzung von klostergang mit dem Kursziel 4,5$ zu.
Überschrift: BDSI quite attractive at current levels
SecteurProduits pharmaceutiques Agenda 15/03 Publication de résultats
BioDelivery Sciences International, Inc. est une société pharmaceutique, qui engage dans le développement etcommercialisation de nouvelles applications thérapeutiques de répondreimportants approuvés pourbesoins médicaux non satisfaits.
Il se concentre sur les produits pharmaceutiques dans les domaines de la gestion de la douleur et de la toxicomanie.
La société a été fondée le 6 janvier 1997 et son siège est à Raleigh, en Caroline du Nord.
Nombre d'employés : 116 personnes.
Neueste Beiträge
Bankster in Biodexa Pharmaceuticals Plc diskutieren